Success Metrics

Clinical Success Rate

100.0%

Based on 4 completed trials

Completion Rate

100%(4/4)

Active Trials

0(0%)

Results Posted

0%(0 trials)

Phase Distribution

Ph phase_1

25%

Ph not_applicable

50%

Ph phase_4

25%

Phase Distribution

Early Stage

Mid Stage

Late Stage

Phase Distribution4 total trials

Phase 1Safety & dosage

1(25.0%)

Phase 4Post-market surveillance

1(25.0%)

N/ANon-phased studies

2(50.0%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

100.0%

4 of 4 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

trials recruiting

Total Trials

all time

Status Distribution

Completed(4)

Detailed Status

Completed4

Development Timeline

Analytics

Development Status

Total Trials

Active

Success Rate

100.0%

Most Advanced

Phase 4

Trials by Phase

Phase 11 (25.0%)

Phase 41 (25.0%)

N/A2 (50.0%)

Trials by Status

completed4100%

Recent Activity

0 active trials

Showing 4 of 4

completedphase_4

Systemic Lidocaine Versus Ultrasound-guided Adductor Canal Block for Patients Undergoing Total Knee Arthroplasty

NCT04828083

completednot_applicable

Lidocaine Infusion With ERAS Protocol for Pancreatic Cancer Surgery: Effect on Pain and Patient Immunity.

NCT05470166

completednot_applicable

Effect of Lidocaine Plus Dexmedetomidine Infusion on PONV

NCT03788018

completedphase_1

A Study of Metyrapone and Oxazepam Combination Product (EMB-001) and Cocaine

NCT02856854

Clinical Trials (4)

Showing 4 of 4 trials

NCT04828083Phase 4

Systemic Lidocaine Versus Ultrasound-guided Adductor Canal Block for Patients Undergoing Total Knee Arthroplasty

Completed

NCT05470166Not Applicable

Lidocaine Infusion With ERAS Protocol for Pancreatic Cancer Surgery: Effect on Pain and Patient Immunity.

Completed

NCT03788018Not Applicable

Effect of Lidocaine Plus Dexmedetomidine Infusion on PONV

Completed

NCT02856854Phase 1

A Study of Metyrapone and Oxazepam Combination Product (EMB-001) and Cocaine

Completed

All 4 trials loaded

Drug Details

Intervention Type: DRUG
Total Trials: 4